GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verrica Pharmaceuticals Inc (FRA:1NE) » Definitions » Price-to-Owner-Earnings

Verrica Pharmaceuticals (FRA:1NE) Price-to-Owner-Earnings : (As of May. 22, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Verrica Pharmaceuticals Price-to-Owner-Earnings?

As of today (2024-05-22), Verrica Pharmaceuticals's share price is €7.865. Verrica Pharmaceuticals does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Verrica Pharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:


FRA:1NE's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.52
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-22), Verrica Pharmaceuticals's share price is €7.865. Verrica Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-1.63. Therefore, Verrica Pharmaceuticals's PE Ratio for today is At Loss.

As of today (2024-05-22), Verrica Pharmaceuticals's share price is €7.865. Verrica Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was €-1.58. Therefore, Verrica Pharmaceuticals's PE Ratio without NRI for today is At Loss.


Verrica Pharmaceuticals Price-to-Owner-Earnings Historical Data

The historical data trend for Verrica Pharmaceuticals's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verrica Pharmaceuticals Price-to-Owner-Earnings Chart

Verrica Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

Verrica Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Verrica Pharmaceuticals's Price-to-Owner-Earnings

For the Biotechnology subindustry, Verrica Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verrica Pharmaceuticals's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verrica Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Verrica Pharmaceuticals's Price-to-Owner-Earnings falls into.



Verrica Pharmaceuticals Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Verrica Pharmaceuticals's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=7.865/-1.43
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Verrica Pharmaceuticals  (FRA:1NE) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Verrica Pharmaceuticals Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Verrica Pharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Verrica Pharmaceuticals (FRA:1NE) Business Description

Traded in Other Exchanges
Address
44 West Gay Street, Suite 400, West Chester, PA, USA, 19380
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its lead product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts.

Verrica Pharmaceuticals (FRA:1NE) Headlines

No Headlines